Quark Biosciences, Inc. of Hsinchu at MEDICA 2021 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option

Quark Biosciences, Inc.

6-2, Shengyi Rd., Sec. 2, 4f-1, Zhubei,, 302058 Hsinchu
Taiwan

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
TAITRA Taiwan External Trade Development Council

Hall map

MEDICA 2021 hall map (Hall 16): stand C36

Fairground map

MEDICA 2021 fairground map: Hall 16

Contact

Debby Chang

Marketing Director

Phone
+886-3-6590898 ext. 630

Email
debbychang@quarkbiosciences.com

Clio Huang

Marketing Manager

Phone
+886-3-6590898 ext. 631

Email
cliohuang@quarkbiosciences.com

Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Other molecular diagnostics testing

Our products

Product category: Other molecular diagnostics testing

NextAmp™ Analysis System

A dual functioning system capable of multi-biomarkers analysis and digital detection of low quantity nucleic acids.

  • Application focuses:  1 ) Precision Oncology 2) Reproductive Genetics
  • 100 biomarker multiplexing: deliver ready-to-use assays with simple operation and capacity to analyze up to 100 biomarkers simultaneously
  • 2-hour turnaround time: with results available in as little as one day vs an average of 14 days for NGS
  • High accuracy & reproducibility: 1% sensitivity vs 5% sensitivity for NGS Panels
  • Simple to use: just one step is needed to load the sample into thousands of reaction wells and perform the experiment
  • Ideal for decentralization: Simple-to-use platform requires minimal investment in training, capital efficient and physically small platform is a viable option in a greater range of clinics
  • More affordable: at least 3x less than NGS in cost 

More Less

Product category: Other molecular diagnostics testing

MIRA™

The next generation microRNA-based endometrial receptivity analysis
for IVF patients with a success rate of over 70%

  • Providing a less invasive test by utilizing low sample amounts
  • Utilizing novel biomarkers of a more stable nature, increasing the stability of the test while reducing the overall fail rate
  • Simpler and faster operation time, shortening the turnaround time of the analysis and providing a speedier sample to data workflow
  • Our quantitative amplification-based platform with higher reproducibility compared to NGS
  • Easy-to-use, enabling decentralized labs to provide high quality service with consistency in numerous locations

More Less

Product category: Other molecular diagnostics testing

MoDEL™

A highly sensitive liquid biopsy for Real-time EGFR mutation monitoring in NSCLC
for progression and drug resistance

1. Liquid Biopsy: Allowing detection of acquired drug resistance mutations in plasma
2. High sensitivity: Detection limit of 0.1% VAF (variant allele frequency), 10X more sensitive than conventional qPCR
3. Actionable mutations: Simultaneously analyzing classical sensitizing EGFR mutations and T790M in a timely manner
4. Real-time detection: Simple and efficient operation, providing results in less than one day

More Less

About us

Company portrait

--We Make Molecular Diagnostics Easy
--ISO13485 certificated
--CE Marked

Quark Biosciences, Inc was built on the vision of using the most innovative technologies to provide rapid, affordable precision healthcare solutions, in real-time, to patients around the globe. This is what gets us up in the morning and pushes us every day to find quicker, better, more accurate solutions in the fields of precision oncology and reproductive genetics.

QuarkBio has developed a groundbreaking new diagnostic solution, the NextAmp™ Analysis System, that combines the advantages and eliminates the disadvantages of existing technologies, addressing the challenges faced by the clinical testing field of precision medicine. The gene-chip-based diagnostic platform is designed to allow users to analyze up to 100 biomarkers in under two hours with minimal hands on time.

The system is built on the ideal of accessibility. In the context of QuarkBio, accessibility refers to:
• The affordable nature of the technology (for both patients, institutions, clinics)
• The intuitive functionality of the system (for institutions, clinics)
• The expedited, collaborative assay development process resulting from QuarkBio’s technology and know-how (for pharma, institutions, and, as an extension, patients)

QuarkBio’s team of eighty experts have committed hundreds of thousands of R&D hours over the past decade to redefine what high quality precision healthcare means and how it can be made accessible to the people who need it most. Our system is the high-powered result of this labor, enabling decentralized testing that generates on-the-spot results. Because at QuarkBio, we know that every minute matters, and every life is important.

Company data

Number of employees 50-99
Area of business
  • Laboratory equipment
  • Diagnostic tests